<DOC>
	<DOCNO>NCT00990340</DOCNO>
	<brief_summary>The purpose study obtain psychological response user preference information use T jet® device versus traditional subcutaneous injection administration Tev Tropin® . This study compare subject-reported injection anxiety immediately administration dose Tev-Tropin® needle-syringe injection method needle-free injection method ( T-jet® )</brief_summary>
	<brief_title>Comparison Needle-free Injection Method With Needle-syringe Injection Method</brief_title>
	<detailed_description>The primary efficacy endpoint difference mean subject-reported injection anxiety two injection method record 5-point FIS immediately administration . A high score denote great anxiety . The injection anxiety score report subject row five face value range 5 ( face negative affect ) 1 ( face positive affect ) .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Subjects must require routine TevTropin® dose exceed 2.5 mg one injection ( 0.5 mL ) use dose schedule individualize patient prescribe physician Male , age 717 year , capability provide assent , determine investigator and/or parent legal guardian Clinically definite growth hormone deficiency previously diagnose investigator physician Subjects must use TevTropin® prior enrollment 28 day Informed consent sign parent ( ) legal custodian patient prior study entry patient assent determine investigator and/or subject 's parent legal custodian More one subcutaneous injection per TevTropin® dose Female gender Use needlefree injection device time Current use another human growth hormone product TevTropin® Concurrent treatment routine injectable medication History benign intracranial hypertension Significant communication difficulty , medical psychiatric condition , affect subject 's and/or caregiver 's ability perform necessary function complete study , condition investigator medical judgment think may interfere participation study Use investigational drug within 30 day prior randomization Contraindications relate routine use TevTropin® per investigator ' medical judgment ( e.g. , subject close epiphysis , active proliferative severe nonproliferative diabetic retinopathy , active malignancy , acute critical illness , PraderWilli syndrome severely obese severe respiratory impairment ) Current participation another pharmaceutical device study Previous participation study</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>